Media Relations News Releases Year: - Any -2019201820172016 Items per page 102550 Jul 30, 2018 Summary ToggleNovartis marks a new era for migraine patients with the EU approval of Aimovig®, a first-of-its-kind treatment specifically designed for migraine prevention Jul 18, 2018 Summary ToggleNovartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women Jun 29, 2018 Summary ToggleNovartis receives positive CHMP opinion for Kymriah® for treating two aggressive blood cancers, marking important medical advance for patients in Europe Jun 28, 2018 Summary ToggleNovartis presents new data demonstrating long-term efficacy, safety and tolerability of Aimovig® (erenumab) in patients with chronic and episodic migraine Jun 27, 2018 Summary ToggleGlobal study by Novartis and European Migraine and Headache Alliance reveals 60% of employed people with severe migraine miss, on average, a week of work per month Jun 27, 2018 Summary ToggleGlobal study by Novartis and European Migraine and Headache Alliance reveals 60% of employed people with severe migraine miss, on average, a week of work per month Jun 1, 2018 Summary ToggleNovartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine May 17, 2018 Summary ToggleNovartis and Amgen announce FDA approval of Aimovig™ (erenumab), a novel treatment developed specifically for migraine prevention May 15, 2018 Summary ToggleNovartis successfully completes acquisition of AveXis, Inc. May 11, 2018 Summary ToggleNovartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis Pagination First page First Previous page Previous … Page 3 Current page 4 Page 5 Page 6 … Next page Next Last page Last
